{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:32Z","timestamp":1791646472681,"version":"4.3.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The principal underlying inhaled antibiotic treatment in bronchiectasis is that airway bacterial load drives inflammation, and therefore antibiotic treatment will reduce symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the relationship between bacterial load and clinical outcomes, assess the stability of bacterial load over time, and test the hypothesis that response to inhaled antibiotics would be predicted by baseline bacterial load.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed three studies. Studies 1 and 2 were prospective studies including adults with bronchiectasis. Study 3 was a post hoc analysis of a randomized trial of inhaled aztreonam. A priori patients were divided into low (&amp;lt;105 cfu\/g), moderate (105\u2013106 cfu\/g), and high bacterial load (\u2265107 cfu\/g) using quantitative sputum culture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Bacterial load was a stable trait associated with worse quality of life and more airway inflammation in studies 1, 2, and 3. In study 3, patients with high bacterial load showed an improvement in the primary endpoint (Quality of Life\u2013Bronchiectasis\u2013Respiratory Symptoms Score at Week 4) in favor of aztreonam (mean difference of 9.7 points; 95% confidence interval, 3.4\u201316.0; P\u2009=\u20090.003). The proportion of patients who achieved an increase above the minimum clinically important difference was higher in the aztreonam group at Week 4 (63% vs. 37%; P\u2009=\u20090.01) and at Week 12 (62% vs. 38%; P\u2009=\u20090.01) only in high bacterial load patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Improvement of quality of life with inhaled aztreonam was only evident in patients with high bacterial load. Bacterial load may be a useful biomarker of severity of disease and treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201809-1651oc","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T03:02:47Z","timestamp":1558407767000},"page":"33-41","source":"Crossref","is-referenced-by-count":108,"title":["Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis"],"prefix":"10.1093","volume":"200","author":[{"given":"Oriol","family":"Sibila","sequence":"first","affiliation":[{"name":"Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Biomedical Research Institute Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Laserna","sequence":"additional","affiliation":[{"name":"Hospital Comarcal de Mollet, Mollet del Vall\u00e9s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Shoemark","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly R.","family":"Keir","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Finch","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rodrigo-Troyano","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Biomedical Research Institute Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Perea","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Lonergan","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter C.","family":"Goeminne","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, AZ Nikolaas, Sint-Niklaas, Belgium; and"},{"name":"Department of Respiratory Medicine, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"2026030321314017800_bib1","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030321314017800_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030321314017800_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"2026030321314017800_bib5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026030321314017800_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib7","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321314017800_bib8","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321314017800_bib9","first-page":"A7604","article-title":"Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT3 and ORBIT4)","volume-title":"Am J Respir Crit Care Med","author":"Haworth","year":"2017"},{"key":"2026030321314017800_bib10","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321314017800_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","article-title":"Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis","volume":"55","author":"Chalmers","year":"2013","journal-title":"Mol Immunol"},{"key":"2026030321314017800_bib12","first-page":"6","article-title":"Inflammation: a two-edged sword\u2013the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"2026030321314017800_bib13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.164.9.2105083","article-title":"Bronchial inflammation and colonization in patients with clinically stable bronchiectasis","volume":"164","author":"Angrill","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9343(00)00507-6","article-title":"Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis","volume":"109","author":"Hill","year":"2000","journal-title":"Am J Med"},{"key":"2026030321314017800_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12931-014-0114-1","article-title":"Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease","volume":"15","author":"Singh","year":"2014","journal-title":"Respir Res"},{"key":"2026030321314017800_bib17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib19","doi-asserted-by":"crossref","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321314017800_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"},{"key":"2026030321314017800_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration","volume":"48","author":"Aliberti","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321314017800_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"Papi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/17476348.2017.1360769","article-title":"Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox","volume":"11","author":"Eapen","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2026030321314017800_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321314017800_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.200912-1843CC","article-title":"Chronic obstructive pulmonary disease phenotypes: the future of COPD","volume":"182","author":"Han","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/1\/33\/67169153\/ajrccm_200_1_33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/1\/33\/67169153\/ajrccm_200_1_33.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:31:53Z","timestamp":1772591513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/200\/1\/33\/8496779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,7,1]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201809-1651oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,7,1]]}}}